We remain upbeat on the Brainstorm story, and nothing reported from the Phase 2a trial has altered our impression of the company or the potential for NurOwn™. Thus, we are reiterating our ‘Buy’ rating and maintaining a $10 price target. Less
investors know this is going to $150
Sentiment: Strong Buy
@adamfeuerstein Jan 14th BLUE Webcasting #JPM15 Breakout Session / post.
bought some today.